Related references
Note: Only part of the references are listed.Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2022)
DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates With HPV Status, Mutational Load, an Interferon-γ Signature, Signatures of Immune Infiltrates, and Survival
Sophia M. Loick et al.
JOURNAL OF IMMUNOTHERAPY (2022)
Harnessing cytokines and chemokines for cancer therapy
David J. Propper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
PD-L1 expression in recurrent head and neck squamous cell carcinoma
Alice Delafoy et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2022)
PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis
Long Chen et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2022)
EGFR Mutations in Head and Neck Squamous Cell Carcinoma
Sindhu Nair et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Extracellular matrix proteins regulate NK cell function in peripheral tissues
Mark D. Bunting et al.
SCIENCE ADVANCES (2022)
An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma
Yaxuan Huang et al.
FRONTIERS IN ONCOLOGY (2022)
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials
Bharat Goel et al.
TRANSLATIONAL ONCOLOGY (2022)
Exosome-mediated remodeling of the tumor microenvironment: From local to distant intercellular communication
Yujuan Huang et al.
CANCER LETTERS (2022)
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)
J. Chandra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Oncolytic virotherapy: Challenges and solutions
Nasser Hashemi Goradel et al.
CURRENT PROBLEMS IN CANCER (2021)
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma
Jose A. Monteiro de Oliveira Novaes et al.
CANCER PREVENTION RESEARCH (2021)
Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Naoya Kitamura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma
Xueying Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
The cancer metabolic reprogramming and immune response
Longzheng Xia et al.
MOLECULAR CANCER (2021)
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen et al.
NATURE COMMUNICATIONS (2021)
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J. Luke et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
Sara Labiano et al.
CLINICAL CANCER RESEARCH (2021)
DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
Chuan Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Joel Guigay et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
A. Argiris et al.
ANNALS OF ONCOLOGY (2021)
Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Ganping Wang et al.
CANCER LETTERS (2021)
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
Hasan Baysal et al.
FRONTIERS IN IMMUNOLOGY (2021)
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Robert L. Ferris et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)
Julia Siemert et al.
CANCERS (2021)
The Ratio of Preoperative Serum Biomarkers Predicts Prognosis in Patients With Oral Squamous Cell Carcinoma
Meng Ding et al.
FRONTIERS IN ONCOLOGY (2021)
TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
Meredith L. Stone et al.
JCI INSIGHT (2021)
Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma
Teng Wei et al.
ONCOIMMUNOLOGY (2021)
Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model
Sonia Domingos-Pereira et al.
ONCOIMMUNOLOGY (2021)
Changes in Protein Glycosylation in Head and Neck Squamous Cell Carcinoma
Chengcheng Liao et al.
JOURNAL OF CANCER (2021)
OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway
Xin Pang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
Joris B. W. Elbers et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Yu Fu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Tumor angiogenesis: causes, consequences, challenges and opportunities
Roberta Lugano et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis
Jaimin J. Patel et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma
Qiang Li et al.
FRONTIERS IN ONCOLOGY (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model
Soon-Hyun Ahn et al.
ANTICANCER RESEARCH (2020)
Recent advances of oncolytic virus in cancer therapy
Moumita Mondal et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer
Ramireddy Bommireddy et al.
VACCINES (2020)
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Kevin J. Harrington et al.
CLINICAL CANCER RESEARCH (2020)
Two-year follow-up of a randomized phaseIIIclinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate141)
Chia-Jui Yen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
Claire Smalley Rumfield et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV plus R/M HNSCC)
C. Aggarwal et al.
ANNALS OF ONCOLOGY (2020)
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Bonnie S. Glisson et al.
CLINICAL CANCER RESEARCH (2020)
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
David H. Peng et al.
NATURE COMMUNICATIONS (2020)
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
Jonathan D. Schoenfeld et al.
JAMA ONCOLOGY (2020)
New emerging targets in cancer immunotherapy: the role of GITR
Giulia Buzzatti et al.
ESMO OPEN (2020)
A review on development of MUC1-based cancer vaccine
Tong Gao et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
Yungan Tao et al.
EUROPEAN JOURNAL OF CANCER (2020)
Overexpression of LncRNA SNHG1 Were Suitable for Oncolytic Adenoviruse H101 Therapy in Oral Squamous-Cell Carcinoma
Xin Wang et al.
ONCOTARGETS AND THERAPY (2020)
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Victoria Atkinson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma
Chumin Zhou et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2020)
Genomic and immunologic correlates of LAG-3 expression in cancer
Anshuman Panda et al.
ONCOIMMUNOLOGY (2020)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H. Segal et al.
EUROPEAN JOURNAL OF CANCER (2019)
Simultaneous T Cell Activation and Macrophage Polarization to Promote Potent Tumor Suppression by Iron Oxide-Embedded Large-Pore Mesoporous Organosilica Core-Shell Nanospheres
Lin Chen et al.
ADVANCED HEALTHCARE MATERIALS (2019)
Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies
Jessica D. McDermott et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Tumoral microvesicle-activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma
Erhui Jiang et al.
FASEB JOURNAL (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
Kayla V. Myers et al.
MOLECULAR CANCER (2019)
Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
Masahiro Ogasawara et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2019)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2019)
CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15-and IL-21-Driven NK Cell Proliferation
Laurent Vidard et al.
JOURNAL OF IMMUNOLOGY (2019)
Cancer-associated fibroblast-derived exosomal miR-382-5p promotes the migration and invasion of oral squamous cell carcinoma
Li-Ping Sun et al.
ONCOLOGY REPORTS (2019)
The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial
Donald T. Weed et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Exosomes in Head and Neck Squamous Cell Carcinoma
Cheng Xiao et al.
FRONTIERS IN ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma
Peng Liao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Metabolic pathways of L-arginine and therapeutic consequences in tumors
Jaroslaw Szefel et al.
ADVANCES IN MEDICAL SCIENCES (2019)
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells
Heng Dong et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer
Y. S. Tan et al.
JOURNAL OF DENTAL RESEARCH (2018)
Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma
W-W Deng et al.
ORAL DISEASES (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon et al.
SEMINARS IN CANCER BIOLOGY (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
IL-10 in the microenvironment of HNSCC inhibits the CpG ODN-induced IFN-α secretion of pDCs
Karl-Ludwig Bruchhage et al.
ONCOLOGY LETTERS (2018)
Immunocompetence and mechanism of the DRibble-DCs vaccine for oral squamous cell carcinoma
Heng Dong et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells
Nils Ludwig et al.
MOLECULAR CANCER RESEARCH (2018)
Transforming growth factor- signaling in head and neck squamous cell carcinoma: Insights into cellular responses
Xin Pang et al.
ONCOLOGY LETTERS (2018)
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors
Ben Tran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p
Yao-yin Li et al.
EBIOMEDICINE (2018)
SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1
Hui Liu et al.
NANOSCALE RESEARCH LETTERS (2018)
Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
Kim Ohl et al.
FRONTIERS IN IMMUNOLOGY (2018)
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype
Bei Wang et al.
SCIENCE IMMUNOLOGY (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma
Kenichi Shinagawa et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
Jennifer D. Moy et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Alcohol and head and neck cancer
Daisuke Kawakita et al.
CANCER AND METASTASIS REVIEWS (2017)
Metabolic reprograming of anti-tumor immunity
Madhusudhanan Sukumar et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy
Anne-Kristin Vahle et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma
Theresa L. Whiteside et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation
Ce Wang et al.
BIOMATERIALS (2016)
A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus-associated cancers
Miriam Reuschenbach et al.
CANCER (2016)
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
Alfonso R. Sanchez-Paulete et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Exosomes and tumor-mediated immune suppression
Theresa L. Whiteside
JOURNAL OF CLINICAL INVESTIGATION (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis et al.
ORAL ONCOLOGY (2016)
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
Ameet K. Mishra et al.
ONCOTARGET (2016)
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Sebastian Carotta
FRONTIERS IN IMMUNOLOGY (2016)
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
Wei-Wei Deng et al.
ONCOIMMUNOLOGY (2016)
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
C. H. Chung et al.
ANNALS OF ONCOLOGY (2015)
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Hideyuki Takahashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Nutrient Competition: A New Axis of Tumor Immunosuppression
Madhusudhanan Sukumar et al.
CELL (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC
Pan Jiang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids
Stephan Kloess et al.
FRONTIERS IN IMMUNOLOGY (2015)
Overcoming the toxicity hurdles of genetically targeted T cells
Monica Casucci et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
Dan P. Zandberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
Yoshihiro Yoshitake et al.
CLINICAL CANCER RESEARCH (2015)
Integrating Novel Therapeutic Monoclonal Antibodies Into the Management of Head and Neck Cancer
Julie E. Bauman et al.
CANCER (2014)
Releasing Pressure in Tumors: What Do We Know So Far and Where Do We Go from Here? A Review
Arlizan B. Ariffin et al.
CANCER RESEARCH (2014)
Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
Patrick J. Schuler et al.
CLINICAL CANCER RESEARCH (2014)
Regulatory T cells in cancer immunotherapy
Hiroyoshi Nishikawa et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie et al.
BRITISH JOURNAL OF CANCER (2013)
Macrophage Regulation of Tumor Responses to Anticancer Therapies
Michele De Palma et al.
CANCER CELL (2013)
Current status of interleukin-10 and regulatory T-cells in cancer
Kristen L. Dennis et al.
CURRENT OPINION IN ONCOLOGY (2013)
Monocyte CD40 expression in head and neck squamous cell carcinoma (HNSCC)
Devendra Sathawane et al.
HUMAN IMMUNOLOGY (2013)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients
Paramita Baruah et al.
IMMUNOBIOLOGY (2012)
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Mark Agulnik
MEDICAL ONCOLOGY (2012)
Glucose, Not Glutamine, Is the Dominant Energy Source Required for Proliferation and Survival of Head and Neck Squamous Carcinoma Cells
Vlad C. Sandulache et al.
CANCER (2011)
THERAPEUTIC EFFECTS OF A FUSOGENIC NEWCASTLE DISEASE VIRUS IN TREATING HEAD AND NECK CANCER
Pingdong Li et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
Marta Osorio Rodriguez et al.
CANCER BIOLOGY & THERAPY (2010)
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma
Ajay Matta et al.
HEAD & NECK ONCOLOGY (2009)
Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model
Aditya Ambade et al.
CANCER LETTERS (2008)
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells
Paolo Serafini et al.
CANCER RESEARCH (2008)
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
Lars Bastholt et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Transforming growth factor-β and the immune response:: Implications for anticancer therapy
Stephen H. Wrzesinski et al.
CLINICAL CANCER RESEARCH (2007)
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer
Stephane Temam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation
SL Lu et al.
CANCER RESEARCH (2004)
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
WK Bleeker et al.
JOURNAL OF IMMUNOLOGY (2004)
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
J Nemunaitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers
ML Gillison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
JP Lamont et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Share Paper
